THE PROLASTIN DIRECT® PROGRAM CONNECTS YOUR PATIENTS TO ALPHANET'S DISEASE MANAGEMENT PROGRAM

The AlphaNet® Alpha-1 Disease Management and Prevention Program (ADMAPP) is the only fully integrated disease management program shown to improve patient outcomes1,2*

Disease management health outcomes study results:

Significant improvements in health outcomes after intervention year (n=878)2
10%
reduction in exacerbations2 Ρ<0.001
12%
reduction in unscheduled physician visits2 Ρ=0.03
21%
reduction in emergency room visits2 Ρ=0.02
10%
increase in the use of long-term oxygen therapy (>16 hours/day)2 Ρ<0.01
15%
increase in use of long-acting bronchodilator2 Ρ<0.001
  • Translates into more optimal medication use
Reduction in the use of systemic steroids2 Ρ=0.02
Significant improvements in health outcomes after intervention year (n=878)2
10%
reduction in exacerbations2 Ρ<0.001
12%
reduction in unscheduled physician visits2 Ρ=0.03
21%
reduction in emergency room visits2 Ρ=0.02
10%
Increase in the use of long-term oxygen therapy (>16 hours/day)2 Ρ<0.01
15%
increase in long-acting bronchodilator use2 Ρ<0.001
  • Translates into more optimal medication use
Reduction in the use of systemic steroids2 Ρ=0.02

*2-year study comparing outcomes in a 12-month observation period with augmentation therapy alone and a 12-month intervention period with augmentation therapy plus ADMAPP2.

  • Participants were members of AlphaNet, a not-for-profit health management company founded by alphas to provide comprehensive care solely for alphas
  • 97% of ADMAPP study participants were taking PROLASTIN® (alpha1-proteinase inhibitor [human])2

Enrolled patients immediately start receiving ADMAPP benefits through AlphaNet1


PROLASTIN®-C LIQUID is an alpha1-proteinase inhibitor (human) (alpha1-PI) indicated for chronic augmentation and maintenance therapy in adults with clinical evidence of emphysema due to severe hereditary deficiency of alpha1-PI (alpha1-antitrypsin deficiency).

Limitations of Use


  • The effect of augmentation therapy with any alpha1-PI, including PROLASTIN-C LIQUID, on pulmonary exacerbations and on the progression of emphysema in alpha1-PI deficiency has not been conclusively demonstrated in randomized, controlled clinical trial
  • Clinical data demonstrating the long-term effects of chronic augmentation or maintenance therapy with PROLASTIN-C LIQUID are not available
  • PROLASTIN-C LIQUID is not indicated as therapy for lung disease in patients in whom severe alpha1-PI deficiency has not been established

PROLASTIN-C LIQUID is contraindicated in immunoglobulin A (IgA)-deficient patients with antibodies against IgA or patients with a history of anaphylaxis or other severe systemic reaction to alpha1-PI products.

Hypersensitivity reactions, including anaphylaxis, may occur. Monitor vital signs and observe the patient carefully throughout the infusion. If hypersensitivity symptoms occur, promptly stop PROLASTIN-C LIQUID infusion and begin appropriate therapy.

Because PROLASTIN-C LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents, eg, viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens.

The most common adverse reactions during PROLASTIN-C LIQUID clinical trials in >5% of subjects were diarrhea and fatigue, each of which occurred in 2 subjects (6%).

Please see full Prescribing Information for PROLASTIN-C LIQUID.


References

  1. Data on file, PROLASTIN DIRECT program.
  2. Campos MA, Alazemi S, Zhang G, Wanner A, Sandhaus RA. Effects of a disease management program in individuals with alpha-1 antitrypsin deficiency. COPD. 2009;6(1):31-40.